Table 3 Summary of comparison of costs and QALYs (deterministic base-case), Canadian $
Parameter | Cost: as-needed budesonide-formoterol | Cost: low-dose maintenance ICS + as-needed SABA | Incremental Cost ($) | QALY: as-needed budesonide-formoterol | QALY: low-dose maintenance ICS + as-needed SABA | Incremental QALYs |
|---|---|---|---|---|---|---|
Non-exacerbation | $1146.16 | $1145.89 | $0.27 | 25.875 | 25.869 | 0.006 |
Severe exacerbation | $3010.65 | $2847.82 | $162.83 | 0.047 | 0.052 | − 0.004 |
Drug costs | $4268.32 | $7943.94 | − $3675.62 | N/A | N/A | N/A |
Adverse events | $28,013.94 | $34,384.33 | − $6370.39 | 0.000 | 0.000 | 0.000 |
Total | $36,439.08 | $46,321.98 | − $9882.90 | 25.923 | 25.921 | 0.002 |